Inhalerx Ltd Cash Flow Conversion Efficiency

Latest as of June 2025: -0.044x

Inhalerx Ltd cash flow conversion efficiency. Based on the latest financial reports, Inhalerx Ltd (IRX) has a cash flow conversion efficiency ratio of -0.044x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$38.91K ≈ $27.53K USD) by net assets (AU$-877.11K ≈ $-620.61K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Inhalerx Ltd (2016–2024)

Cash flow conversion efficiency of Inhalerx Ltd from 2016 to 2024. This chart illustrates how Inhalerx Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Inhalerx Ltd for real-time trading data and today's change.

Inhalerx Ltd Cash Flow Conversion Ratio Explained

Inhalerx Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Inhalerx Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Inhalerx Ltd ranked by their cash flow conversion efficiency. Also see market value of Inhalerx Ltd for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Nicoccino Holding AB ST:NICO	-0.936x
Anagenics Ltd AU:AN1	-0.099x
Henderson International Income Trust PLC LSE:HINT	0.024x
Capitan Investment Ltd V:CAI	0.042x
ASIA Capital Group Public Company Limited BK:ACAP	0.032x
Mitra International Resources JK:MIRA	0.005x
JPMorgan Asia Growth & Income plc LSE:JAGI	0.008x
Harfang Exploration Inc V:HAR	-0.102x

Annual Cash Flow Conversion Efficiency for Inhalerx Ltd (2016–2024)

The table below shows the annual cash flow conversion efficiency of Inhalerx Ltd from 2016 to 2024. Review Inhalerx Ltd (IRX) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	AU$-63.97K ≈ $-45.26K	AU$-368.77K ≈ $-260.93K	5.765x	+295.55%
2023-12-31	AU$665.47K ≈ $470.86K	AU$-1.96 Million ≈ $-1.39 Million	-2.948x	-203.82%
2022-12-31	AU$1.90 Million ≈ $1.35 Million	AU$-1.85 Million ≈ $-1.31 Million	-0.970x	-126.23%
2021-12-31	AU$2.68 Million ≈ $1.89 Million	AU$-1.15 Million ≈ $-812.69K	-0.429x	+47.70%
2020-12-31	AU$1.32 Million ≈ $936.76K	AU$-1.09 Million ≈ $-768.25K	-0.820x	+85.05%
2019-12-31	AU$340.08K ≈ $240.63K	AU$-1.87 Million ≈ $-1.32 Million	-5.487x	-613.06%
2018-12-31	AU$2.68 Million ≈ $1.90 Million	AU$-2.06 Million ≈ $-1.46 Million	-0.770x	-35.45%
2017-12-31	AU$4.51 Million ≈ $3.19 Million	AU$-2.56 Million ≈ $-1.81 Million	-0.568x	-1717.88%
2016-12-31	AU$7.33 Million ≈ $5.19 Million	AU$-229.03K ≈ $-162.05K	-0.031x	--

About Inhalerx Ltd

AU:IRX Australia Biotechnology

Market Cap

$4.18 Million

AU$5.91 Million AUD

Market Cap Rank

#28843 Global

#1545 in Australia

Share Price

AU$0.02

Change (1 day)

+4.35%

52-Week Range

AU$0.02 - AU$0.04

All Time High

AU$0.39